Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Artio Medical

Request full access

Formerly Metactive Medical. Develops endovascular medical devices for the embolization of vessels, aneurysms, and other vascular structures

Prairie Village, United StatesFounded 2014Biotech & Life Sciences

About Artio Medical

Artio Medical, Inc., operating from its base in Prairie Village, Kansas, is a medical device company concentrated on the development of novel endovascular products. The firm was established in 2013 under the name Metactive Medical, a venture that originated from technology developed at Texas A&M University. A significant milestone was achieved in 2017 when the company rebranded to Artio Medical. The company is spearheaded by founder and CEO F. Nicholas Franano, MD, a seasoned entrepreneur in the life sciences sector with previous experience founding and leading other successful biotech and medical device companies.

The company's strategic focus is on addressing unmet needs within the peripheral vascular, neurovascular, and structural heart markets. Artio Medical's business model revolves around the design, development, and commercialization of these specialized devices, targeting hospitals and interventional specialists as its primary client base. Revenue generation is anticipated through the sale of its medical devices upon regulatory approval and market launch.

Artio's product pipeline features several key technologies. The Solus Gold Embolization Device, which received FDA 510(k) clearance in 2019, is designed for peripheral vascular occlusion. Its flexible, non-porous, balloon-like design allows for immediate and permanent vessel blockage, intended to simplify procedures and improve patient outcomes. Another key product is the Amplifi Vein Dilation System, a super-elastic nitinol device that aims to prepare veins for arteriovenous fistula creation in hemodialysis patients, a market with a significant clinical need. The company is also advancing its Comaneci and Endura Aneurysm Net products for the treatment of cerebral aneurysms, showcasing a broad approach to endovascular therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
65.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Jul 2020
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2022 $28M $112M Undisclosed ↗
SERIES AOther financing Apr 2021 $12M $48M Nathaniel Hagedorn · Sarah Hagedorn —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Artio Medical website traffic

Latest recorded traffic for Artio Medical is 620 monthly website visits. Artio Medical's team declined 15.4% over the past year.

Latest monthly visits620 1-year team growth-15.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Artio Medical in the Prairie Village ecosystem

Live from Dealroom

The Artio Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A6 investors entered at this stage

  • Kansas Bioscience Authority
  • Serra Ventures
  • All investments through Mid-America Angels:
  • Activate Venture Partners
  • Nathaniel Hagedorn
  • Sarah Hagedorn

Series B and later1 investor entered at this stage

  • Novita Therapeutics

Other known investors1 additional known investor

  • Texas A&M University
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Artio Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Artio Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.